AUTX-703

A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
69 patients (estimated)
Sponsors
Auron Therapeutics, Inc.
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
2088
NCT Identifier
NCT06846606

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.